Molecular PharmaceuticsPub Date : 2026-11-02Epub Date: 2026-09-26DOI: 10.1021/acs.molpharmaceut.6c00618
Mike A. Cornejo, Gina Dehlavi, Zachary V. Samuels, Wei-Siang Mark Kao, Lukas M. Carter, Emilia Strugala, Yutian Feng, Michael R. Zalutsky, Brian M. Zeglis
{"title":"Radiohalogenated Tetrazines for Click Chemistry-Mediated Pretargeted Radioimmunotherapy","authors":"Mike A. Cornejo, Gina Dehlavi, Zachary V. Samuels, Wei-Siang Mark Kao, Lukas M. Carter, Emilia Strugala, Yutian Feng, Michael R. Zalutsky, Brian M. Zeglis","doi":"10.1021/acs.molpharmaceut.6c00618","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00618","url":null,"abstract":"<p><em>In vivo</em> pretargeting is an emergent approach to nuclear imaging and radiopharmaceutical therapy that leverages the exquisite selectivity and affinity of full-length immunoglobulins while skirting their pharmacokinetic and dosimetric limitations. One particularly promising approach to pretargeting is predicated on the inverse electron-demand Diels−Alder reaction between a <em>trans</em>-cyclooctene (TCO)-bearing antibody and a tetrazine (Tz)-based radioligand. This methodology has been validated with a wide variety of antibody-antigen systems paired with radionuclides for positron emission tomography (PET), single photon emission computed tomography (SPECT), and radioimmunotherapy. The halogen group of the periodic table offers an abundance of isotopes that emit β<sup>−</sup>-particles (<em>i</em>.<em>e</em>. <sup>131</sup>I), α-particles (<em>i</em>.<em>e</em>. <sup>211</sup>At), and Auger electrons (<em>i</em>.<em>e</em>. <sup>125</sup>I) for radiopharmaceutical therapy. Herein, we describe the synthesis and characterization of a pair of Tz radioligands containing <sup>131</sup>I-labeled residualizing guanidinium prosthetic groups: iso-[<sup>131</sup>I]GMIB-PEG<sub>6</sub>-Tz and iso-[<sup>131</sup>I]GMIB-Tz. Subsequently, these two radioligands were used in conjunction with a TCO-bearing variant of the A33 antigen-targeting mAb huA33 (<em>i</em>.<em>e</em>. huA33-TCO) for <em>in vivo</em> pretargeting experiments in a murine model of colorectal carcinoma. The biodistribution and dosimetry data from these preclinical experiments suggested that the PEG<sub>6</sub>-containing radioligand offered a superior pharmacokinetic profile, and protocols were developed for the synthesis of iso-[<sup>211</sup>At]AGMB-PEG<sub>6</sub>-Tz. Finally, the <em>in vivo</em> behavior of iso-[<sup>211</sup>At]AGMB-PEG<sub>6</sub>-Tz was probed in both healthy mice and in a pretargeting system paired with huA33-TCO in a murine model of colorectal carcinoma.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5538–5548"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149306048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Design, Synthesis, and Evaluation of 99mTc-Labeled Proline Isonitrile Derivatives with Optimized Linker Lengths for Tumor SPECT Imaging","authors":"Qing Ruan, Guangxing Yin, Junhong Feng, Dajie Ding, Peiwen Han, Yuhao Jiang, Junbo Zhang","doi":"10.1021/acs.molpharmaceut.6c00846","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00846","url":null,"abstract":"<p>Amino acid metabolic imaging is among the important research directions in tumor molecular imaging. The highly active metabolism of proline in tumors, together with the abnormal expression of its key enzymes, makes it a promising target for tumor molecular imaging. To develop new proline transport-targeted tumor imaging agents, four <span>l</span>-proline isonitrile ligands (CN5Pro, CN6Pro, CN7Pro and CN8Pro) were synthesized and labeled with technetium-99m. All the complexes achieved >95% labeling yield with good stability. Biodistribution in S180 tumor-bearing mice revealed that [<sup>99m</sup>Tc]Tc-CN7Pro exhibited the highest tumor uptake (1.05 ± 0.09% ID/g), a tumor/muscle ratio of 5.03, and predominant renal excretion. With respect to U87MG models, tumor uptake reached 2.47 ± 0.39% ID/g, confirming tumor imaging applicability. SPECT/CT imaging clearly revealed tumors, with uptake inhibited by excess <span>l</span>-proline. Cellular studies indicated uptake primarily via system A transporters, and the complex remained intact in vivo. Collectively, [<sup>99m</sup>Tc]Tc-CN7Pro is convenient for labeling, achieves excellent targeting, and is very stable, making it a promising SPECT tumor imaging agent.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5821–5832"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149306084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Molecular PharmaceuticsPub Date : 2026-11-02Epub Date: 2026-10-08DOI: 10.1021/acs.molpharmaceut.6c00483
Remant KC, Mohammad Nasrullah, Daniel Nisakar Meenakshi Sundaram, Dev Patel, Gurkirat Sandhu, Cezary Kucharski, Hasan Uludağ
{"title":"mRNA Delivery with Lipopolymers to Rejuvenate TRAIL Therapy for Lung Cancer Treatment","authors":"Remant KC, Mohammad Nasrullah, Daniel Nisakar Meenakshi Sundaram, Dev Patel, Gurkirat Sandhu, Cezary Kucharski, Hasan Uludağ","doi":"10.1021/acs.molpharmaceut.6c00483","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00483","url":null,"abstract":"<p>Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) has long been identified as a promising therapeutic due to its ability to induce apoptosis selectively in cancer cells. However, poor stability and rapid clearance of the administered TRAIL protein in circulation have hampered its clinical development. With recent advances in the mRNA technology, this study explored the potential of a lung cancer therapy by delivering TRAIL mRNA using lipopolymers. Here, we show that a leading cationic lipopolymer (mRNA-Fect) can package mRNA into nanoparticles (ζ-potential +14.9 to −8.6 mV with a 200−400 nm diameter, as observed by DLS measurement), thereby enhancing transfection efficiency in lung cancer cells. When tested with an mRNA encoding the reporter GFP gene (<em>m</em>-GFP), the lipopolymer induced GFP expression as early as 4 hours, reaching optimal expression by 24 hours, with a high transfection efficiency in lung cancer cells (GFP-positive population: 50−80%). Delivering an <em>m</em>-TRAIL led to TRAIL protein secretion as early as 2 hours post-transfection, significantly reducing viability (∼80%) and activating caspase-3/-7 in lung cancer cells. The lipopolymer successfully expressed reporter genes following intramuscular, subcutaneous, and intravenous administration in animal models. Furthermore, delivery of <em>m</em>-TRAIL suppressed tumor growth in a local lung cancer xenograft model, demonstrating therapeutic potential in the absence of any adverse effects. We conclude that mRNA-Fect-formulated <em>m</em>-TRAIL could be a potent therapy of lung cancers, showing promise for broader therapeutic applications in the future.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5412–5425"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149305644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Molecular PharmaceuticsPub Date : 2026-11-02Epub Date: 2026-10-14DOI: 10.1021/acs.molpharmaceut.6c00375
Tianyun Zhang, Md Abdullah Shamim, Cole W. Tower, Rachana Sapkota, Nicholas J. Huls, Dahui Liu, Kang Chen, Haiou Qu, Wenlei Jiang, Yan Wang, Deyi Zhang, Eric J. Munson
{"title":"Characterization of Carboxymaltose Structure and Interactions with the Iron Core in Ferric Carboxymaltose (Injectafer) Using NMR Spectroscopy","authors":"Tianyun Zhang, Md Abdullah Shamim, Cole W. Tower, Rachana Sapkota, Nicholas J. Huls, Dahui Liu, Kang Chen, Haiou Qu, Wenlei Jiang, Yan Wang, Deyi Zhang, Eric J. Munson","doi":"10.1021/acs.molpharmaceut.6c00375","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00375","url":null,"abstract":"<p>Ferric carboxymaltose (FCM), marketed as Injectafer, is an intravenous iron formulation used to treat iron deficiency. It is composed of polynuclear Fe(III)-oxyhydroxide/oxide cores surrounded by carboxymaltose. Although it has been on the market for over 10 years, the structure of carboxymaltose and its interaction with the iron core are not fully understood. This study used nuclear magnetic resonance (NMR) to investigate both the structure of carboxymaltose and how it interacts with the iron core in Injectafer. Carboxymaltose was isolated from Injectafer and compared with other carboxymaltose samples made from maltodextrin with various dextrose equivalents (DEs). The results showed that carboxymaltose from Injectafer resembles most closely a lab-synthesized carboxymaltose with a DE of 4−7. Carboxymaltotriose was also synthesized to help with assigning the peaks in the NMR spectra of carboxymaltose. NMR was also used to study Injectafer in its as-is and diluted form. Compared to the spectra of diluted samples, peaks of the as-is sample were broadened and downfield-shifted in the <sup>13</sup>C NMR spectra of Injectafer, due to the presence of iron and possibly due to interactions of carboxymaltose with the iron core. <sup>1</sup>H NMR spectra of significantly diluted Injectafer showed <sup>1</sup>H NMR peaks adjacent to the carboxy group only at dilutions of 400× or more, whereas the other peaks were observed at 100×. This suggests that the carboxy group interacts with the iron core and that it separates from the core at higher dilutions. Competitive binding studies using both low- and high-molecular-weight carboxymaltose, along with trimethylsilyl propionate (TSP), were used to characterize the binding affinity of carboxy groups to the iron core, as well as the maximum amount of carboxy groups that can bind to the surface of the iron core in Injectafer.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5327–5340"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149305648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Molecular PharmaceuticsPub Date : 2026-11-02Epub Date: 2026-10-12DOI: 10.1021/acs.molpharmaceut.6c00624
Justyna Knapik-Kowalczuk, Mariya Mathew, Paulina Poloczek, Tianyun Zhang, Nicholas J. Huls, Julia Cichocka-Łokuciejewska, Mateusz Dulski, Eric J. Munson, Marian Paluch
{"title":"Non-Monotonic Glass Transition Behavior as a Molecular Signature of Strong Interactions in Co-Amorphous and Crystalline Celecoxib-Etoricoxib Systems","authors":"Justyna Knapik-Kowalczuk, Mariya Mathew, Paulina Poloczek, Tianyun Zhang, Nicholas J. Huls, Julia Cichocka-Łokuciejewska, Mateusz Dulski, Eric J. Munson, Marian Paluch","doi":"10.1021/acs.molpharmaceut.6c00624","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00624","url":null,"abstract":"<p>Co-amorphous API−API systems often exhibit improved physical stability compared to their neat amorphous counterparts. This effect, however, becomes less straightforward when both components possess nearly identical glass transition temperatures (T<sub>g</sub>). In this work, we investigate a model celecoxib + etoricoxib (CEL + ETO) system, in which both APIs display comparable T<sub>g</sub> and molecular dynamics, yet markedly different physical stability. Using differential scanning calorimetry (DSC), broadband dielectric spectroscopy (BDS), Fourier-transform infrared spectroscopy (FTIR), and solid-state Nuclear Magnetic Resonance spectroscopy (ssNMR), we demonstrate that CEL + ETO mixtures exhibit a rare, non-monotonic dependence of T<sub>g</sub> on composition, with a maximum near the equimolar ratio. This behavior is consistently observed across independent techniques and deviates from conventional mixing rules. Despite only moderate changes in molecular mobility, co-amorphization with ETO leads to a pronounced suppression of CEL recrystallization, as confirmed by dielectric studies. Spectroscopic data reveal strong heteromolecular interactions, including hydrogen-bonded heterosynthons, which disrupt CEL self-association and hinder nucleation. Importantly, these interactions may also influence the crystalline phase, where deviations from ideal eutectic behavior and sensitivity to mechanical treatment indicate non-ideal, preparation-dependent crystalline-phase behavior and possible mechanically induced crystalline rearrangements. These findings suggest that non-monotonic T<sub>g</sub> − composition dependence can serve as a signature of strong intermolecular interactions and provide a link between amorphous-phase behavior and crystalline-phase organization.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5549–5561"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149305711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Molecular PharmaceuticsPub Date : 2026-11-02Epub Date: 2026-10-20DOI: 10.1021/acs.molpharmaceut.6c00839
Zhao-Lin Ding, Han Gao, Zi-Ting Xu, Huan-Fang Xie, Jia-Yi Lv, Wen-Lin An, Min Han, Binguo Shen, Wei-Jie Fang
{"title":"Poloxamer 188 Promotes Severe Aggregation of Insulin under Shaking Conditions","authors":"Zhao-Lin Ding, Han Gao, Zi-Ting Xu, Huan-Fang Xie, Jia-Yi Lv, Wen-Lin An, Min Han, Binguo Shen, Wei-Jie Fang","doi":"10.1021/acs.molpharmaceut.6c00839","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00839","url":null,"abstract":"<p>Insulin is an indispensable cornerstone in the management of diabetes mellitus, yet its extreme susceptibility to aggregation under mechanical stress remains a formidable challenge for long-term formulation stability. This study investigates the potential of Poloxamer 188 (P188) as a chemically stable alternative to the industry-standard Polysorbate 20 (PS20) for stabilizing insulin. Formulations containing graded concentrations of P188 (0.005%−0.15%, w/v), 0.05% (w/v) PS20, or no surfactant were subjected to 24 h shaking stress at 300 rpm. Our results reveal a striking concentration-dependent profile for P188, where 0.05% PS20 consistently maintains robust protection, whereas low-to-moderate concentrations of P188 (0.005%−0.05%) fail to stabilize insulin and instead exert a pronounced “pro-aggregatory” effect. At 0.05% P188, this pro-aggregatory behavior leads to severe macroscopic turbidity, a massive surge in particle concentration (≥2 μm), and the near-total disappearance of detectable insulin monomers in the supernatant. Crucially, elevating the P188 concentration to 0.15% effectively prevents macroscopic turbidity and preserves high soluble protein recovery. Mechanistically, the instability observed at low-to-moderate P188 concentrations stems from its sluggish interfacial adsorption kinetics compared to PS20, leaving nascent air-liquid interfaces temporarily unprotected. Under such conditions, P188 functions as a macromolecular scaffold and nucleation core, cross-linking interface-denatured proteins with native molecules to drive rapid co-assembly. These findings serve as a critical warning for the biopharmaceutical industry that the use of P188 in insulin-based products must be approached with extreme caution to avoid inadvertent protein aggregation.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5799–5807"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149305908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Crystallization Behavior of Amorphous Solid DispersionsRole of Nucleation and Nucleation Density","authors":"Bhushan Munjal, Snehal Shukla, Aifang Li, Alpana Thorat, Debbie Wanapun, Aaron Baldwin, Kapildev K. Arora, Raj Suryanarayanan","doi":"10.1021/acs.molpharmaceut.6c00648","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00648","url":null,"abstract":"<p>The <em>T</em><sub>nose</sub> for nucleation (i.e., the temperature of the maximum nucleation rate without any crystal growth) of flurbiprofen-polyvinylpyrrolidone amorphous solid dispersions (ASDs) was determined using the time−temperature−transformation (TTT) diagram. Varying levels of nucleation were induced in ASDs by annealing for different time periods at <em>T</em><sub>nose</sub> for nucleation. Synchrotron X-ray diffractometry was utilized for real-time monitoring of the crystallization behavior upon wetting the ASDs with water. An increase in the nucleation density shortened the lag time and also accelerated drug crystallization. Williamson−Hall analysis of the X-ray data revealed a progressive reduction in the lattice strain (increased lattice order) of the crystallizing phase with increasing contact time with water. From performance perspectives, actualizing the solubility advantage of the amorphous drug necessitates retaining supersaturation for a sufficiently long period to allow absorption from the gastrointestinal tract. However, the presence of nuclei, by facilitating crystallization, can negate the solubility and the consequent bioavailability advantage of ASDs. A systematic framework for evaluating the “health” of ASDs was established, highlighting that the absence of nuclei would be an essential attribute of robust ASDs.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5562–5571"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149305640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Molecular PharmaceuticsPub Date : 2026-11-02Epub Date: 2026-10-12DOI: 10.1021/acs.molpharmaceut.6c00775
Xiaoyang Li, Yan Ming, Xiaodan Wang, Rongtao Li, Yun Yang, Teng Yang, Jing Wang, Baiyu Chang, Qing Zhang, Jingling Tang, Jiaxin Liu, Hongyu Ji, Congcong Lin
{"title":"Injectable Thermosensitive Hydrogel Synergizes Antibacterial Action with Microenvironment Remodeling in Infected Diabetic Wounds","authors":"Xiaoyang Li, Yan Ming, Xiaodan Wang, Rongtao Li, Yun Yang, Teng Yang, Jing Wang, Baiyu Chang, Qing Zhang, Jingling Tang, Jiaxin Liu, Hongyu Ji, Congcong Lin","doi":"10.1021/acs.molpharmaceut.6c00775","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00775","url":null,"abstract":"<p>Chronic wounds represent substantial clinical challenges due to their intricate pathophysiology, characterized by persistent infection, sustained inflammation, and compromised tissue regeneration. To overcome these obstacles, we developed an injectable thermosensitive hydrogel system (MR-NPs-Gels), incorporating engineered PLGA nanoparticles (MR-NPs) for the co-delivery of mupirocin, a first-line antibacterial agent, and <span>l</span>-arginine, a nitric oxide (NO) precursor. The MR-NPs-Gels exhibited favorable injectability, tissue adaptability, and ideal rheological properties. MR-NPs penetrated deep into tissues to exert antibacterial effects, while <span>l</span>-arginine released from them generated NO to exert anti-inflammatory and pro-angiogenic effects. In diabetic wound models, MR-NPs-Gels achieved a 77.39 ± 1.19% wound closure rate and more than 80% reduction in bacterial colony counts by day 9. Compared with commercial mupirocin ointment, this hydrogel significantly downregulated pro-inflammatory cytokines IL-6 and TNF-α, while upregulating angiogenic markers VEGF and CD31. Collectively, the co-delivery of mupirocin and <span>l</span>-arginine within MR-NPs-Gels enhances bacterial clearance and remodels the wound microenvironment synergistically, offering a promising topical therapeutic strategy for infected chronic wounds.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5657–5673"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149305710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"68Ga-NOTA-FAPI-IF7: A Heterobivalent PET Probe for Dual-Targeted Imaging of Fibroblast Activation Protein and Annexin A1 in Tumor Microenvironment","authors":"Wenfang Liao, Xiaotian Guo, Peng Jiang, Kejing Shao, Bao Zhu, Fei Chen","doi":"10.1021/acs.molpharmaceut.6c01158","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c01158","url":null,"abstract":"<p>Fibroblast activation protein (FAP)-targeted PET tracers enable high-contrast tumor imaging but suffer from rapid clearance and non-specific uptake in inflammatory lesions. The heptapeptide IF7 binds annexin A1 (ANXA1) on tumor vascular endothelium, a target directly accessible from the bloodstream. To overcome these limitations, we developed a heterobivalent PET probe, NOTA-FAPI-IF7, based on a rationally designed dual-targeting strategy that simultaneously engages FAP in cancer-associated fibroblasts and ANXA1 on tumor vasculature. Radiolabeling with <sup>68</sup>Ga achieved a radiochemical yield of 92.3 ± 3.6% (decay-corrected, <em>n</em> = 5) with excellent stability (radiochemical purity >97% at all time points). In vitro assays confirmed dual-target binding (IC<sub>50</sub> = 27.9 nM, <em>K</em><sub>D</sub> = 3.77 nM). Micro-PET imaging demonstrated rapid tumor visualization as early as 10 min post-injection (6.02 ± 0.07% ID/g), with uptake significantly reduced by blocking with excess unlabeled FAPI, IF7, or NOTA-FAPI-IF7. The probe exhibited favorable hydrophilicity (log <em>P</em> = −1.20) and renal clearance with low hepatobiliary uptake. This bispecific strategy, distinct from monospecific and homomultimeric approaches, offers a promising avenue for precision oncologic PET imaging.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5936–5945"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149305643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Molecular PharmaceuticsPub Date : 2026-11-02Epub Date: 2026-10-09DOI: 10.1021/acs.molpharmaceut.6c00816
Hui Xu, Rong Zhang, Lu Zhao, Yunfeng Bai, Feng Feng
{"title":"NIR-II-Accelerated 2D-on-2D Silicene/MOF Heterointerfaces Disrupt Tumor Redox Homeostasis for Targeted Ferroptosis","authors":"Hui Xu, Rong Zhang, Lu Zhao, Yunfeng Bai, Feng Feng","doi":"10.1021/acs.molpharmaceut.6c00816","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00816","url":null,"abstract":"<p>Catalytic ferroptosis therapy provides an attractive approach for tumor treatment, but its practical efficacy is often limited by insufficient reaction kinetics and the strong redox buffering capacity of the tumor microenvironment. Herein, we report an interface-engineered 2D-on-2D catalytic nanoplatform, SNs/FTC@Apt-P (SFTCP), constructed by integrating silicene nanosheets with an ultrathin Fe−Cu metal−organic framework and further functionalized with a PD-L1 aptamer for tumor targeting. The silicene/Fe−Cu metal−organic framework heterointerface offers abundant exposed catalytic sites and facilitates interfacial electron transfer, improving Fenton-like catalytic activity under biologically relevant conditions. At the biointerface, Fe<sup>3+</sup>/Cu<sup>2+</sup> bimetallic centers consume intracellular glutathione (GSH) and weaken the xCT/GSH/GPX4 antioxidant defense pathway, thereby reducing the ability of tumor cells to eliminate lipid peroxides. Under NIR-II irradiation, SFTCP generates localized photothermal stimulation that acts as an external kinetic accelerator to further enhance catalytic oxidative stress. This interface-mediated and photothermally amplified process promotes lipid peroxide accumulation and induces ferroptotic tumor cell death. In vivo, aptamer-mediated targeting combined with NIR−II−augmented catalysis increases intratumoral lipid peroxidation and achieves 87% tumor growth inhibition with favorable biosafety. This work demonstrates an applied interface-engineering strategy for constructing catalytic nanomaterials that integrate redox regulation, photothermal activation, and ferroptosis-based tumor therapy.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5718–5734"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149305660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}